Kura Oncology (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Zacks.com reports. The brokerage presently has a $19.00 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 18.90% from the stock’s current price.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other research firms have also weighed in on KURA. Citigroup raised their target price on shares of Kura Oncology from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 24th. BidaskClub raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. ValuEngine raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, March 27th. HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $27.83.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 7th. The company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.08. Sell-side analysts forecast that Kura Oncology will post -1.77 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in Kura Oncology by 9.7% during the third quarter. Bank of New York Mellon Corp now owns 112,255 shares of the company’s stock worth $1,965,000 after buying an additional 9,884 shares in the last quarter. Teachers Advisors LLC grew its stake in Kura Oncology by 20.1% in the 3rd quarter. Teachers Advisors LLC now owns 51,013 shares of the company’s stock valued at $893,000 after purchasing an additional 8,536 shares during the period. Vanguard Group Inc. grew its stake in Kura Oncology by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,455,818 shares of the company’s stock valued at $25,477,000 after purchasing an additional 29,785 shares during the period. Fosun International Ltd bought a new position in Kura Oncology in the 4th quarter valued at $2,643,000. Finally, Rhumbline Advisers grew its stake in Kura Oncology by 59.1% in the 4th quarter. Rhumbline Advisers now owns 37,118 shares of the company’s stock valued at $521,000 after purchasing an additional 13,781 shares during the period. 83.93% of the stock is currently owned by hedge funds and other institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: What is a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.